Clinical trial data are coming thick and fast for anti-CGRP therapies, and extensive studies are underway to bring additional understanding of their role in migraine treatment and in potential non-migraine indications. Take a look at our recently updated summaries of results from key trials and catch up with new and ongoing research.
Aimovig (erenumab): new efficacy data from EMPOwER in episodic migraine in patients in Asia, the Middle East and Latin America, as well as 5-year follow up results from study NCT01952574 in episodic migraine, and more...
Ajovy (fremanezumab): additional data from the FOCUS trial including longer term open label follow up, together with 12-month data from HALO, and recruitment progress on paediatric and non-migraine studies, and more...
Emgality (galcanezumab): additional results from the CONQUER study in treatment-resistant migraine, and post hoc analyses from study NCT2397473 in episodic cluster headache, and more...
Vyepti (eptinezumab): new PROMISE 2 sub-group analysis in patients with chronic migraine and medication overuse headache, and news of ongoing studies in episodic cluster headache (ALLEVIATE) and hard-to-treat migraine, and more...
Ubrelvy (ubrogepant): recently reported pharmacokinetic data from study NCT0417974 in patients treated with ubrogepant and erenumab or galcanezumab, plans for the PRODROME study investigating efficacy and safety during the migraine prodrome, and more...
Nurtec (rimegepant): newly published data from study NCT03732638 in migraine prevention, safety data awaiting publication from study NCT03266588, and recruitment updates on paediatric studies and study NCT03941834 in refractory trigeminal neuralgia, and more...
Atogepant: extensive published data from study NCT02848326 in episodic migraine prevention, and recruitment news on a growing range of studies in episodic and chronic migraine, including in hard-to-treat patients, and more...
For all the other recent migraine news featured on the CGRP Forum, catch up at: News
If you’d like to contribute your experiences of using anti-CGRP therapies or share CGRP research findings, please get in touch. |
